Invasive Non-typhoidal
Salmonella (iNTS) Vaccines Forecast
Invasive non-typhoidal Salmonella (iNTS) is one of the most lethal bacterial infections of young children in sub-Saharan Africa, and there is still no licensed vaccine. VAMV095 is VacZine Analytics' independent commercial assessment of the opportunity for iNTS-containing vaccines. It brings together disease burden, a registry-verified pipeline and a country-level demand and revenue forecast for sub-Saharan Africa.
- Format
- PDF executive deck + Excel forecast model
- Markets modelled
- 49 sub-Saharan African countries
- Scenarios
- Uptake, pricing, launch & dosing
- Forecast horizon
- To 2047
- Approach
- Demand & revenue forecast
- Status
- In preparation
- Availability
- Syndicated / bespoke
(WHO, IHME 2019 estimates)
14.5% case fatality (41.8% in people living with HIV)
blood isolates, sub-Saharan Africa (2024 meta-analysis)
to date
A high-mortality bacterial disease now carrying a WHO high-priority AMR designation
This section sets out the disease background and epidemiology of invasive non-typhoidal Salmonella (iNTS) disease, which is concentrated in sub-Saharan Africa and is increasingly drug resistant.
Pathogen overview - invasive non-typhoidal Salmonella
Invasive non-typhoidal Salmonella (iNTS) disease is a bloodstream infection caused predominantly by Salmonella Typhimurium and, to a lesser extent, Salmonella Enteritidis. In high-income settings these serovars typically cause self-limited enterocolitis, but across sub-Saharan Africa a distinct invasive phenotype has emerged, presenting as bacteraemia or sepsis rather than gastrointestinal illness, and the disease is far more lethal there. The authoritative burden estimate, drawn from IHME/GBD 2019 data and cited by WHO, is approximately 594,000 cases and 79,000 deaths worldwide in 2019, equivalent to 6.11 million DALYs, with an overall case fatality rate of 14.5%, rising to 41.8% in people living with HIV.
Risk is driven by a cluster of comorbidities common across the region. Malaria, HIV infection, malnutrition, anaemia and sickle cell disease all independently elevate susceptibility to invasive disease, and young children bear the heaviest burden. This comorbidity profile distinguishes iNTS from many other vaccine-preventable diseases on VacZine Analytics' coverage list: it is a burden concentrated by poverty and coincident infection as much as by direct pathogen transmissibility.
Antimicrobial resistance is the defining and worsening feature of the current disease picture. A 2024 systematic review and meta-analysis of non-typhoidal Salmonella in sub-Saharan Africa pooled multidrug resistance across blood isolates at 68.5% (95% CI 57.4-77.8%), across 66 studies. Drug-resistant lineages, notably ST313 lineage 2, are spreading across sub-Saharan Africa, eroding the utility of standard antibiotic regimens and strengthening the case for prevention over treatment. WHO lists iNTS as a High priority on its Bacterial Priority Pathogens List.
A phase 2 field led by two trivalent conjugate candidates
The clinical field is now in phase 2, led by trivalent iNTS-typhoid conjugate candidates from GSK Vaccines Institute for Global Health and from the University of Maryland Center for Vaccine Development with Bharat Biotech. Bivalent candidates are also in development. Every clinical candidate in the report is verified against trial registries.
-
GSK / GVGHPhase 2a, The GambiaiNTS-TCV (GSK4077164) Trivalent conjugate vaccine
A 537-participant, single-centre Phase 2a trial in infants in The Gambia, including dose and schedule finding and age de-escalation, started in April 2026 and registered on ClinicalTrials.gov (NCT07286370). -
University of Maryland, Baltimore / Bharat BiotechPhase 2, MaliTrivalent Salmonella Conjugate Vaccine (TSCV) Typhoid + iNTS conjugate
An age-descending, placebo-controlled Phase 2 trial registered at the Centre for Vaccine Development in Bamako, Mali (NCT05784701, 800 participants), run by the University of Maryland with Bharat Biotech as collaborator. -
GSK / GVGHPhase 2a completediNTS-GMMA (bivalent) Generalised Modules for Membrane Antigens
A single-centre, age-de-escalation Phase 2a trial in Africa (NCT06213506, 180 participants) of GSK/GVGH's bivalent S. Typhimurium and S. Enteritidis GMMA vaccine is registered as completed. -
Boston Children's Hospital / GSK-AffinivaxPreclinical, BMGF-fundedBivalent and quadrivalent MAPS candidates Multiple Antigen Presenting System
Preclinical candidates earlier in development behind the clinical-stage programmes, funded by the Bill & Melinda Gates Foundation.
VAMV095 is VacZine Analytics' independent commercial assessment of the iNTS vaccine opportunity. It brings together disease burden, a registry-verified pipeline and a country-level demand and revenue forecast for sub-Saharan Africa. A companion module covering South and Southeast Asia and valency options is in preparation.
Six analytical layers - one commercial picture
A sub-Saharan Africa analysis spanning demand and revenue forecasting, scenarios, country-level outputs, a registry-verified pipeline, target product profile context and disease burden. A companion module covering South and Southeast Asia and valency options is in preparation.
Demand and revenue forecast to 2047 for an infant iNTS-typhoid combination conjugate vaccine across 49 sub-Saharan African countries, covering Gavi-supported and self-financing markets.
Scenarios on uptake, pricing, launch timing and dosing schedule, including booster options.
Doses and revenue by country, year and buyer segment.
Registry-verified review of the clinical iNTS field, led by GSK/GVGH's iNTS-TCV and the University of Maryland/Bharat Biotech TSCV.
Target product profile, launch timing and pricing context.
Burden and epidemiology, updated to the latest available data.
A glimpse of the commercial model
The table below shows a partial view of the market-segment and scenario framework. Full revenue outputs, scenario assumptions and country-level data are in the licensed model.
| Market segment | Geography | Sector | Vaccine status | Revenue scenario |
|---|---|---|---|---|
| Infant routine immunisation | 49 sub-Saharan African countries | Gavi-supported and self-financing | Pre-licensure | Modelled |
| Infant catch-up | 49 sub-Saharan African countries | Gavi-supported and self-financing | Pre-licensure | Modelled |
| Infant booster | 49 sub-Saharan African countries | Gavi-supported and self-financing | Pre-licensure | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | All countries | All buyer segments | All scenarios | $███m |
What you receive
An executive presentation and a fully interactive forecast model, built for organisations evaluating the iNTS vaccine opportunity across sub-Saharan Africa.
- Executive presentation (PDF) - disease burden, pipeline and the full commercial assessment, with supporting narrative and references
- Excel forecast model - interactive scenario dashboard and country view, with doses and revenue by country, year and buyer segment
- Scenario set - uptake, pricing, launch timing and dosing-schedule scenarios with documented assumptions and sources
- Pipeline and competitor intelligence - registry-verified review of the clinical iNTS field
- Updated epidemiology - disease burden and AMR context, updated to the latest available data
Built for organisations weighing the iNTS vaccine opportunity
Most valuable to teams evaluating the iNTS vaccine market against their own pipeline, BD ambitions or investment thesis, now that the clinical field has reached phase 2.
Vaccine developers
Positioning and commercial feasibility assessment for iNTS candidates at any stage, informed by the phase 2 programmes now under way.
Corporate strategy & BD
Validate the size and structure of a still-open market with no licensed vaccine, using an independent, registry-verified analysis.
Investors & analysts
Independent assessment of pipeline risk and commercial upside for due diligence on GSK, the University of Maryland, Bharat Biotech and future iNTS entrants.
Public health & Gavi-linked bodies
Demand modelling and procurement planning support across sub-Saharan Africa, covering Gavi-supported and self-financing markets.
Researchers & academia
Disease burden, epidemiology and R&D landscape for grant, translational and AMR-surveillance research planning.
Market access & policy
Pricing context and access-pathway assumptions across Gavi-supported procurement and self-financing market channels.
VAMV095 is VacZine Analytics' independent commercial assessment of the opportunity for iNTS-containing vaccines, bringing together disease burden, a registry-verified pipeline and a country-level demand and revenue forecast for sub-Saharan Africa. It is currently in preparation, and a companion module covering South and Southeast Asia and valency options is also in preparation.
The analysis draws on the WHO-cited IHME/GBD 2019 burden estimates (approximately 594,000 cases and 79,000 deaths worldwide) and a pipeline in which every clinical candidate is verified against trial registries. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Register your interest - or commission the answer you need
Register your interest to help shape and secure the syndicated MarketVIEW edition, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc iNTS analysis, a briefing call is included on request.